Serina Therapeutics, Inc.SER

Serina Therapeutics, Inc. Segments Disclosure

10-KFiled Mar 25, 20262 min read
Segment Reporting
The Company has one reportable segment relating to the research and development of its POZ platform. The segment derived its revenues from Grant revenue.
The Company’s CODM, its Chief Executive Officer and the senior executive leadership team manage the Company’s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company’s financial performance, the CODM regularly reviews total revenues and expenses by specific categories to make informed decisions.
The table below is a summary of the segment revenues, including significant segment expenses (in thousands):
Year Ending December 31,
20252024
Revenue$130 $56 
Less:
Research and development
Project specific (1)
6,234 2,962 
Non-Project specific (2)
504 475 
Compensation (3)
5,837 3,462 
Infrastructure Management and Facilities495 363 
Depreciation85 218 
General and administrative
Professional and outside service fees (4)
4,171 3,341 
Compensation (3)
6,339 4,468 
Infrastructure Management and Facilities487 339 
Merger and Integration related— 1,476 
Total operating expenses24,152 17,104 
Loss from operations$(24,022)$(17,048)

(1) Research and development project specific expenses largely consist of costs incurred to develop the Company's lead product candidate, SER 252 (POZ-apomorphine) as well as expenses incurred to develop other small molecules, RNA-based therapeutics and antibody-based drug conjugates ("ADCs").
(2) Research and development non-project specific expenses mainly consists of laboratory expenses and fees paid to outside services.
(3) Compensation includes employee salary and fringe benefits, stock based compensation and compensation to independent contractors.
(4) General and administrative professional and outside service fees mainly consist of legal, accounting and audit, board, insurance, and SEC filing fees.

Historical Timeline

Fiscal YearFiled
2025Mar 25, 2026Showing above
2024Mar 24, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per SharePP&ECommitmentsStock CompensationNew StandardsPay vs Performance